Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 4454 entries
Sorted by: Best Match Show Resources per page
Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer.

OncoTargets and therapy

Ono M, Ito T, Kanai T, Murayama K, Koyama H, Maeno K, Mochizuki Y, Iesato A, Hanamura T, Okada T, Watanabe T, Ito K.
PMID: 24124381
Onco Targets Ther. 2013 Oct 07;6:1393-8. doi: 10.2147/OTT.S51164. eCollection 2013.

Bevacizumab when combined with chemotherapy exerts significant activity against many solid tumors through tumor angiogenesis inhibition; however, it can induce severe side effects. We report the rare case of a 27-year-old premenopausal woman with locally advanced breast cancer that...

Cite
Ono M, Ito T, Kanai T, et al. Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer. Onco Targets Ther. 2013;6:1393-8doi: 10.2147/OTT.S51164.
Ono, M., Ito, T., Kanai, T., Murayama, K., Koyama, H., Maeno, K., Mochizuki, Y., Iesato, A., Hanamura, T., Okada, T., Watanabe, T., & Ito, K. (2013). Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer. OncoTargets and therapy, 61393-8. https://doi.org/10.2147/OTT.S51164
Ono, Mayu, et al. "Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer." OncoTargets and therapy vol. 6 (2013): 1393-8. doi: https://doi.org/10.2147/OTT.S51164
Ono M, Ito T, Kanai T, Murayama K, Koyama H, Maeno K, Mochizuki Y, Iesato A, Hanamura T, Okada T, Watanabe T, Ito K. Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer. Onco Targets Ther. 2013 Oct 07;6:1393-8. doi: 10.2147/OTT.S51164. eCollection 2013. PMID: 24124381; PMCID: PMC3794845.
Copy Download .nbib Format: NLM
A Rare Case of Digital Ischemia and Gangrene in ANCA-Associated Vasculitis with Review of the Literature.

Case reports in rheumatology

Lau RA, Bains R, Suraweera D, Ma J, Heinze ER, Wong AL, Clements PJ.
PMID: 28348913
Case Rep Rheumatol. 2017;2017:2421760. doi: 10.1155/2017/2421760. Epub 2017 Feb 28.

This paper describes one patient with Antineutrophil Cytoplasmic Antibody- (ANCA-) associated vasculitis who initially presented with multiple ischemic fingers and toes. On further evaluation, the patient was also found to have pulmonary-renal involvement and episcleritis. The diagnosis was supported...

Cite
Lau RA, Bains R, Suraweera D, et al. A Rare Case of Digital Ischemia and Gangrene in ANCA-Associated Vasculitis with Review of the Literature. Case Rep Rheumatol. 2017;2017:2421760doi: 10.1155/2017/2421760.
Lau, R. A., Bains, R., Suraweera, D., Ma, J., Heinze, E. R., Wong, A. L., & Clements, P. J. (2017). A Rare Case of Digital Ischemia and Gangrene in ANCA-Associated Vasculitis with Review of the Literature. Case reports in rheumatology, 20172421760. https://doi.org/10.1155/2017/2421760
Lau, Richard A, et al. "A Rare Case of Digital Ischemia and Gangrene in ANCA-Associated Vasculitis with Review of the Literature." Case reports in rheumatology vol. 2017 (2017): 2421760. doi: https://doi.org/10.1155/2017/2421760
Lau RA, Bains R, Suraweera D, Ma J, Heinze ER, Wong AL, Clements PJ. A Rare Case of Digital Ischemia and Gangrene in ANCA-Associated Vasculitis with Review of the Literature. Case Rep Rheumatol. 2017;2017:2421760. doi: 10.1155/2017/2421760. Epub 2017 Feb 28. PMID: 28348913; PMCID: PMC5350346.
Copy Download .nbib Format: NLM
Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab.

Journal of breast cancer

Kim IH, Lee JE, Youn HJ, Song BJ, Chae BJ.
PMID: 28382098
J Breast Cancer. 2017 Mar;20(1):82-90. doi: 10.4048/jbc.2017.20.1.82. Epub 2017 Mar 24.

PURPOSE: We intended to determine whether dexrazoxane (DZR) is cardioprotective during administration of adjuvant anthracycline-based chemotherapy followed by a 1-year trastuzumab treatment.METHODS: The medical records of 228 patients who underwent surgical resection and received adjuvant chemotherapy with trastuzumab for...

Cite
Kim IH, Lee JE, Youn HJ, et al. Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab. J Breast Cancer. 2017;20(1):82-90doi: 10.4048/jbc.2017.20.1.82.
Kim, I. H., Lee, J. E., Youn, H. J., Song, B. J., & Chae, B. J. (2017). Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab. Journal of breast cancer, 20(1), 82-90. https://doi.org/10.4048/jbc.2017.20.1.82
Kim, In-Ho, et al. "Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab." Journal of breast cancer vol. 20,1 (2017): 82-90. doi: https://doi.org/10.4048/jbc.2017.20.1.82
Kim IH, Lee JE, Youn HJ, Song BJ, Chae BJ. Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab. J Breast Cancer. 2017 Mar;20(1):82-90. doi: 10.4048/jbc.2017.20.1.82. Epub 2017 Mar 24. PMID: 28382098; PMCID: PMC5378583.
Copy Download .nbib Format: NLM
Cyclophosphamide induced early-onset interstitial lung disease.

CEN case reports

Ozkok A, Kaymaz S, Elcioglu OC, Bakan A, Odabas AR.
PMID: 28509066
CEN Case Rep. 2012 Nov;1(2):128-129. doi: 10.1007/s13730-012-0021-6. Epub 2012 Jun 06.

No abstract available.

Cite
Ozkok A, Kaymaz S, Elcioglu OC, et al. Cyclophosphamide induced early-onset interstitial lung disease. CEN Case Rep. 2012;1(2):128-129doi: 10.1007/s13730-012-0021-6.
Ozkok, A., Kaymaz, S., Elcioglu, O. C., Bakan, A., & Odabas, A. R. (2012). Cyclophosphamide induced early-onset interstitial lung disease. CEN case reports, 1(2), 128-129. https://doi.org/10.1007/s13730-012-0021-6
Ozkok, Abdullah, et al. "Cyclophosphamide induced early-onset interstitial lung disease." CEN case reports vol. 1,2 (2012): 128-129. doi: https://doi.org/10.1007/s13730-012-0021-6
Ozkok A, Kaymaz S, Elcioglu OC, Bakan A, Odabas AR. Cyclophosphamide induced early-onset interstitial lung disease. CEN Case Rep. 2012 Nov;1(2):128-129. doi: 10.1007/s13730-012-0021-6. Epub 2012 Jun 06. PMID: 28509066; PMCID: PMC5411529.
Copy Download .nbib Format: NLM
Primary Ewing sarcoma of the kidney: a case report and treatment review.

CEN case reports

Sadiq M, Ahmad I, Shuja J, Ahmad K.
PMID: 28509141
CEN Case Rep. 2017 Nov;6(2):132-135. doi: 10.1007/s13730-017-0259-0. Epub 2017 Apr 21.

Ewing sarcomas/primitive neuroectodermal tumors (ES/PNET) of the kidney are rarely found high-grade malignant tumors, offering poor prognosis. Although established treatment guidelines for ES of kidney are scarce, a multi-modality treatment approached is typically implemented. Herein, we report a 14-year-old...

Cite
Sadiq M, Ahmad I, Shuja J, et al. Primary Ewing sarcoma of the kidney: a case report and treatment review. CEN Case Rep. 2017;6(2):132-135doi: 10.1007/s13730-017-0259-0.
Sadiq, M., Ahmad, I., Shuja, J., & Ahmad, K. (2017). Primary Ewing sarcoma of the kidney: a case report and treatment review. CEN case reports, 6(2), 132-135. https://doi.org/10.1007/s13730-017-0259-0
Sadiq, Muhammad, et al. "Primary Ewing sarcoma of the kidney: a case report and treatment review." CEN case reports vol. 6,2 (2017): 132-135. doi: https://doi.org/10.1007/s13730-017-0259-0
Sadiq M, Ahmad I, Shuja J, Ahmad K. Primary Ewing sarcoma of the kidney: a case report and treatment review. CEN Case Rep. 2017 Nov;6(2):132-135. doi: 10.1007/s13730-017-0259-0. Epub 2017 Apr 21. PMID: 28509141; PMCID: PMC5694397.
Copy Download .nbib Format: NLM
Methylprednisolone pulse therapy and intravenous cyclophosphamide therapy combined with cocktail therapy in severe pediatric Henoch-Schönlein purpura nephritis patient.

CEN case reports

Kanai H, Kobayashi A, Matsushita K, Sawanobori E, Sugita K, Higashida K.
PMID: 28509230
CEN Case Rep. 2013 May;2(1):117-122. doi: 10.1007/s13730-012-0056-8. Epub 2013 Jan 12.

Henoch-Schönlein purpura (HSP) is a common self-limited vasculitis in children. The long-term prognosis depends on renal involvement. In severe Henoch-Schönlein purpura nephritis (HSPN) patients, >50 % have crescent formation and nephrotic syndrome that are important predicted outcomes. Therefore, for...

Cite
Kanai H, Kobayashi A, Matsushita K, et al. Methylprednisolone pulse therapy and intravenous cyclophosphamide therapy combined with cocktail therapy in severe pediatric Henoch-Schönlein purpura nephritis patient. CEN Case Rep. 2013;2(1):117-122doi: 10.1007/s13730-012-0056-8.
Kanai, H., Kobayashi, A., Matsushita, K., Sawanobori, E., Sugita, K., & Higashida, K. (2013). Methylprednisolone pulse therapy and intravenous cyclophosphamide therapy combined with cocktail therapy in severe pediatric Henoch-Schönlein purpura nephritis patient. CEN case reports, 2(1), 117-122. https://doi.org/10.1007/s13730-012-0056-8
Kanai, Hiroaki, et al. "Methylprednisolone pulse therapy and intravenous cyclophosphamide therapy combined with cocktail therapy in severe pediatric Henoch-Schönlein purpura nephritis patient." CEN case reports vol. 2,1 (2013): 117-122. doi: https://doi.org/10.1007/s13730-012-0056-8
Kanai H, Kobayashi A, Matsushita K, Sawanobori E, Sugita K, Higashida K. Methylprednisolone pulse therapy and intravenous cyclophosphamide therapy combined with cocktail therapy in severe pediatric Henoch-Schönlein purpura nephritis patient. CEN Case Rep. 2013 May;2(1):117-122. doi: 10.1007/s13730-012-0056-8. Epub 2013 Jan 12. PMID: 28509230; PMCID: PMC5411523.
Copy Download .nbib Format: NLM
Long-term remission of corticosteroid- and cyclophosphamide-resistant Henoch-Schönlein purpura with rituximab.

Scandinavian journal of rheumatology

Bellan M, Pirisi M, Sainaghi PP.
PMID: 26312648
Scand J Rheumatol. 2016 Jan;45(1):83-84. doi: 10.3109/03009742.2015.1058417. Epub 2015 Aug 31.

No abstract available.

Cite
Bellan M, Pirisi M, Sainaghi PP. Long-term remission of corticosteroid- and cyclophosphamide-resistant Henoch-Schönlein purpura with rituximab. Scand J Rheumatol. 2015;45(1):83-84doi: 10.3109/03009742.2015.1058417.
Bellan, M., Pirisi, M., & Sainaghi, P. P. (2016). Long-term remission of corticosteroid- and cyclophosphamide-resistant Henoch-Schönlein purpura with rituximab. Scandinavian journal of rheumatology, 45(1), 83-84. https://doi.org/10.3109/03009742.2015.1058417
Bellan, M, et al. "Long-term remission of corticosteroid- and cyclophosphamide-resistant Henoch-Schönlein purpura with rituximab." Scandinavian journal of rheumatology vol. 45,1 (2016): 83-84. doi: https://doi.org/10.3109/03009742.2015.1058417
Bellan M, Pirisi M, Sainaghi PP. Long-term remission of corticosteroid- and cyclophosphamide-resistant Henoch-Schönlein purpura with rituximab. Scand J Rheumatol. 2016 Jan;45(1):83-84. doi: 10.3109/03009742.2015.1058417. Epub 2015 Aug 31. PMID: 26312648.
Copy Download .nbib Format: NLM
A Safety and Efficacy Study of Medium-Dose Etoposide, Cyclophosphamide and Total Body Irradiation Conditioning Before Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia.

Transplantation direct

Shigematsu A, Ozawa Y, Onizuka M, Fujisawa S, Suzuki R, Atsuta Y, Hatanaka K, Masuko M, Ito T, Kobayashi N, Kato J, Miyamura K, Fukuda T, Morishima Y, Imamura M.
PMID: 27500214
Transplant Direct. 2015 Mar 13;1(2):e8. doi: 10.1097/TXD.0000000000000514. eCollection 2015 Mar.

UNLABELLED: Prognosis for adult patients with acute lymphoblastic leukemia (ALL) has been reported to be approximately 35% to 50%, even after allogeneic stem cell transplantation (allo-SCT). We previously reported retrospective analyses of a conditioning regimen of medium-dose etoposide, cyclophosphamide...

Cite
Shigematsu A, Ozawa Y, Onizuka M, et al. A Safety and Efficacy Study of Medium-Dose Etoposide, Cyclophosphamide and Total Body Irradiation Conditioning Before Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia. Transplant Direct. 2015;1(2):e8doi: 10.1097/TXD.0000000000000514.
Shigematsu, A., Ozawa, Y., Onizuka, M., Fujisawa, S., Suzuki, R., Atsuta, Y., Hatanaka, K., Masuko, M., Ito, T., Kobayashi, N., Kato, J., Miyamura, K., Fukuda, T., Morishima, Y., & Imamura, M. (2015). A Safety and Efficacy Study of Medium-Dose Etoposide, Cyclophosphamide and Total Body Irradiation Conditioning Before Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia. Transplantation direct, 1(2), e8. https://doi.org/10.1097/TXD.0000000000000514
Shigematsu, Akio, et al. "A Safety and Efficacy Study of Medium-Dose Etoposide, Cyclophosphamide and Total Body Irradiation Conditioning Before Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia." Transplantation direct vol. 1,2 (2015): e8. doi: https://doi.org/10.1097/TXD.0000000000000514
Shigematsu A, Ozawa Y, Onizuka M, Fujisawa S, Suzuki R, Atsuta Y, Hatanaka K, Masuko M, Ito T, Kobayashi N, Kato J, Miyamura K, Fukuda T, Morishima Y, Imamura M. A Safety and Efficacy Study of Medium-Dose Etoposide, Cyclophosphamide and Total Body Irradiation Conditioning Before Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia. Transplant Direct. 2015 Mar 13;1(2):e8. doi: 10.1097/TXD.0000000000000514. eCollection 2015 Mar. PMID: 27500214; PMCID: PMC4946459.
Copy Download .nbib Format: NLM
Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management.

Transplantation direct

Nijland ML, Kersten MJ, Pals ST, Bemelman FJ, Ten Berge IJ.
PMID: 27500242
Transplant Direct. 2015 Dec 15;2(1):e48. doi: 10.1097/TXD.0000000000000557. eCollection 2016 Jan.

Posttransplant lymphoproliferative disease (PTLD) is a potentially fatal complication after (solid organ) transplantation, which is highly associated with Epstein-Barr virus (EBV). The EBV-specific cytotoxic T cell response that is essential in controlling the virus in healthy individuals is suppressed...

Cite
Nijland ML, Kersten MJ, Pals ST, et al. Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management. Transplant Direct. 2015;2(1):e48doi: 10.1097/TXD.0000000000000557.
Nijland, M. L., Kersten, M. J., Pals, S. T., Bemelman, F. J., & Ten Berge, I. J. (2016). Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management. Transplantation direct, 2(1), e48. https://doi.org/10.1097/TXD.0000000000000557
Nijland, Marieke L, et al. "Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management." Transplantation direct vol. 2,1 (2016): e48. doi: https://doi.org/10.1097/TXD.0000000000000557
Nijland ML, Kersten MJ, Pals ST, Bemelman FJ, Ten Berge IJ. Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management. Transplant Direct. 2015 Dec 15;2(1):e48. doi: 10.1097/TXD.0000000000000557. eCollection 2016 Jan. PMID: 27500242; PMCID: PMC4946499.
Copy Download .nbib Format: NLM
Shuanghuang Shengbai granule cures myelosuppression and suppresses lung cancer progression: mechanism and therapeutic targets from the aspect of microRNAs.

Oncotarget

Wang S, Xu Z, Wang L.
PMID: 28977934
Oncotarget. 2017 Jul 10;8(37):62154-62166. doi: 10.18632/oncotarget.19129. eCollection 2017 Sep 22.

BACKGROUND: Shuanghuang Shengbai granule is effective in curing cyclophosphamide-induced myelosuppression without promoting lung cancer development. This study aims to investigate its mechanism and therapeutic targets.METHODS: Nude mice with lung cancer were treated with physiological saline (control), cyclophosphamide, or cyclophosphamide...

Cite
Wang S, Xu Z, Wang L. Shuanghuang Shengbai granule cures myelosuppression and suppresses lung cancer progression: mechanism and therapeutic targets from the aspect of microRNAs. Oncotarget. 2017;8(37):62154-62166doi: 10.18632/oncotarget.19129.
Wang, S., Xu, Z., & Wang, L. (2017). Shuanghuang Shengbai granule cures myelosuppression and suppresses lung cancer progression: mechanism and therapeutic targets from the aspect of microRNAs. Oncotarget, 8(37), 62154-62166. https://doi.org/10.18632/oncotarget.19129
Wang, Shuang, et al. "Shuanghuang Shengbai granule cures myelosuppression and suppresses lung cancer progression: mechanism and therapeutic targets from the aspect of microRNAs." Oncotarget vol. 8,37 (2017): 62154-62166. doi: https://doi.org/10.18632/oncotarget.19129
Wang S, Xu Z, Wang L. Shuanghuang Shengbai granule cures myelosuppression and suppresses lung cancer progression: mechanism and therapeutic targets from the aspect of microRNAs. Oncotarget. 2017 Jul 10;8(37):62154-62166. doi: 10.18632/oncotarget.19129. eCollection 2017 Sep 22. PMID: 28977934; PMCID: PMC5617494.
Copy Download .nbib Format: NLM
HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide.

Advances in hematology

Bacigalupo A, Sica S.
PMID: 27143973
Adv Hematol. 2016;2016:7802967. doi: 10.1155/2016/7802967. Epub 2016 Apr 07.

The use of high dose posttransplant cyclophosphamide (PT-CY) introduced by the Baltimore group approximately 10 years ago has been rapidly adopted worldwide and is becoming a standard for patients undergoing unmanipulated haploidentical (HAPLO) transplants. PT-CY has been used following...

Cite
Bacigalupo A, Sica S. HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide. Adv Hematol. 2016;2016:7802967doi: 10.1155/2016/7802967.
Bacigalupo, A., & Sica, S. (2016). HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide. Advances in hematology, 20167802967. https://doi.org/10.1155/2016/7802967
Bacigalupo, Andrea, and Sica, Simona. "HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide." Advances in hematology vol. 2016 (2016): 7802967. doi: https://doi.org/10.1155/2016/7802967
Bacigalupo A, Sica S. HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide. Adv Hematol. 2016;2016:7802967. doi: 10.1155/2016/7802967. Epub 2016 Apr 07. PMID: 27143973; PMCID: PMC4838781.
Copy Download .nbib Format: NLM
Idiopathic Relapsing Thrombotic Thrombocytopenic Purpura with Persistent ADAMTS13 Inhibitor Activity Treated Sequentially with Plasmapheresis, Rituximab, Cyclophosphamide and Splenectomy.

Case reports in oncology

Musa F, Baidas S.
PMID: 26034479
Case Rep Oncol. 2015 Apr 22;8(1):196-9. doi: 10.1159/000381868. eCollection 2015.

We here describe a patient with an idiopathic thrombotic thrombocytopenic purpura (TTP) secondary to an ADAMTS13 inhibitor that continued to be dependent on plasmapheresis until the patient was treated with rituximab. TTP manifestations subsided with rituximab treatment in spite...

Cite
Musa F, Baidas S. Idiopathic Relapsing Thrombotic Thrombocytopenic Purpura with Persistent ADAMTS13 Inhibitor Activity Treated Sequentially with Plasmapheresis, Rituximab, Cyclophosphamide and Splenectomy. Case Rep Oncol. 2015;8(1):196-9doi: 10.1159/000381868.
Musa, F., & Baidas, S. (2015). Idiopathic Relapsing Thrombotic Thrombocytopenic Purpura with Persistent ADAMTS13 Inhibitor Activity Treated Sequentially with Plasmapheresis, Rituximab, Cyclophosphamide and Splenectomy. Case reports in oncology, 8(1), 196-9. https://doi.org/10.1159/000381868
Musa, Faisal, and Baidas, Said. "Idiopathic Relapsing Thrombotic Thrombocytopenic Purpura with Persistent ADAMTS13 Inhibitor Activity Treated Sequentially with Plasmapheresis, Rituximab, Cyclophosphamide and Splenectomy." Case reports in oncology vol. 8,1 (2015): 196-9. doi: https://doi.org/10.1159/000381868
Musa F, Baidas S. Idiopathic Relapsing Thrombotic Thrombocytopenic Purpura with Persistent ADAMTS13 Inhibitor Activity Treated Sequentially with Plasmapheresis, Rituximab, Cyclophosphamide and Splenectomy. Case Rep Oncol. 2015 Apr 22;8(1):196-9. doi: 10.1159/000381868. eCollection 2015. PMID: 26034479; PMCID: PMC4448046.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 4454 entries